Autobahn Therapeutics is a San Diego clinical-stage biotech building small-molecule medicines that reach the brain on purpose. Using a brain-targeting chemistry and prodrug platform, the company tunes where a drug goes - central versus peripheral - to unlock validated CNS biology that has been hard to drug safely. Its lead program, elunetirom (ABX-002), is an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist in Phase 2 trials for major depressive disorder and bipolar depression, backed by more than $200 million in venture funding and a 2026 FDA Fast Track designation.
Vibrant Therapeutics (VibrantX) is a clinical-stage biotechnology company building intelligent, logic-gated antibody therapeutics that switch on only inside diseased tissue. By pairing computational protein design with high-throughput wet-lab validation across its BumbleBee, LogicBee and NeuroBee platforms, Vibrant develops conditionally activated, multi-specific antibody prodrugs for oncology, autoimmune, inflammatory and neurological diseases. Its lead program, VIB305, is a logic-gated masked T-cell engager for EGFR-positive solid tumors that has received FDA IND acceptance.